Seeking Alpha

Gilead results rise on improved product sales, easily beating estimates

  • Gilead Sciences' (GILD) Q4 sales growth was helped by higher sales of GILD's newer HIV drugs: Stribild sales totaled $203M, up from $40M a year earlier, and Complera sales were $262M, more than double last year's level.
  • Q4 Atripla sales +1.8% Y/Y to $933M, Truvada sales -2.2% Y/Y to $814M; antiviral product sales rose 22% to $2.64B, while cardiovascular product sales gained 25% to $268.5M.
  • Sales of the much anticipated new hepatitis C treatment Sovaldi totaled $139M in the final weeks of 2013, after winning FDA approval in early December.
  • Looking to 2014, GILD sees full-year sales of $11.3B-$11.5B, a view that excludes Sovaldi sales.
  • Shares flat AH after rising 4% during regular trading.
From other sites
Comments (7)
  • JT_N
    , contributor
    Comment (1) | Send Message
     
    I don't understand why this stock didn't jump...
    4 Feb, 06:06 PM Reply Like
  • zondlo
    , contributor
    Comments (14) | Send Message
     
    Same here
    4 Feb, 06:18 PM Reply Like
  • zondlo
    , contributor
    Comments (14) | Send Message
     
    That was a big beat !
    4 Feb, 06:20 PM Reply Like
  • 3Tavgreg
    , contributor
    Comments (130) | Send Message
     
    It didn't jump because a lot of it was already priced in. That being said, I listened
    to most of the conference call, and there were a lot of congratulations going around.
    As there were no downside surprises, I think that $GILD will slowly melt up;(taking the macro market into account). As the market and analysts digest this qtr and positive
    guidance,(that didn't even include Suvaldi), I believe price targets will rise, grinding
    the stock price inevidentably higher. I am long $GILD.
    4 Feb, 06:45 PM Reply Like
  • scotttoconnor
    , contributor
    Comment (1) | Send Message
     
    Baked in already....
    4 Feb, 07:17 PM Reply Like
  • Kboyd78
    , contributor
    Comments (157) | Send Message
     
    You guys can bake whatever you want I'm buying as much if this stock as I can afford. That call was awesome they are changing how you treat diseases that used to be a death sentence. Ill invest with these people any day
    5 Feb, 08:30 AM Reply Like
  • john edwin peterson
    , contributor
    Comments (152) | Send Message
     
    Can anyone name a company that has changed the way we deal with previously death sentence diseases. Who else would shell 11 billion on the hope they could find a cure for hep c This company is what free market capitalism is all about. The next time somebody says that America is losing their way and cannot compete on the world stage just say I am proud that we have these people at Gilead
    7 Feb, 12:56 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector